alkermes news - Search News

Stifel Upgrades Alkermes

Alkermes raised to buy by Stifel on increased confidence for ALKS2680

Stifel has upgraded Alkermes (NASDAQ:ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. The investment bank said it is now “very confident” that the drug can succeed in NT1 and be differentiated from Takeda’s (TAK) TAK-861 and “more optimistic" that the drug can succeed in NT2 where TAK-861

ETF Daily News · 8h

Alkermes (NASDAQ:ALKS) Upgraded at Stifel Nicolaus

Stifel Nicolaus upgraded shares of Alkermes (NASDAQ:ALKS – Free Report) from a hold rating to a buy rating in a research note released on Tuesday, Marketbeat Ratings reports. The firm currently has $36.

Fintel on MSN · 2d

Stifel Upgrades Alkermes (ALKS)

Fintel reports that on November 5, 2024, Stifel upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Hold to Buy. Analyst Price Forecast Suggests 33.94% Upside As of October 21, 2024, the average one-year price target for Alkermes is $35.

Business Insider · 3d

Stifel bullish on orexin, upgrades Alkermes to Buy

Stifel upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. After a deep dive on the orexin space, the firm says

14d

Alkermes' Q3 Proprietary Sales Soar 18%

The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...

17h

El Paso healthcare providers explore Vivitrol as a less known addiction treatment

Taking the first step to start addiction treatment is an uphill battle, but what can prove to be harder is keeping on a ...

Benzinga.com3d

A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts

During the last three months, 9 analysts shared their evaluations of Alkermes ALKS, revealing diverse outlooks from bullish to bearish. The table below provides a concise overview of recent ...

Yahoo Finance1d

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

Among the posters, Alkermes presented results from a real-world, retrospective study of healthcare resource utilization (HCRU) and treatment patterns in patients with schizophrenia and patients with ...

12d

Alkermes (NASDAQ:ALKS) Price Target Cut to $30.00

Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...

Alkermes upgraded to Buy from Hold at Stifel

Stifel analyst Paul Matteis upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. Published first on TheFly ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results